Stensland Michael D, Schultz Jennifer F, Frytak Jennifer R
Eli Lilly and Company, Indianapolis, IN 46285, USA.
J Clin Psychiatry. 2008 May;69(5):749-58. doi: 10.4088/jcp.v69n0508.
Bipolar disorder is challenging to diagnose in medical practice.
Our objectives were (1) to determine the rate of depression misdiagnosis in patients previously diagnosed with bipolar disorder in administrative claims, (2) to determine the resulting increased treatment costs, and (3) to verify the misdiagnoses in the medical charts for a subset of patients.
We employed cohort analysis using claims from a large, commercial, U.S. health plan from January 2001 through December 2003. Inclusion criteria included 2 bipolar disorder diagnoses (ICD-9-CM criteria), continuous enrollment for 1 year before and after initial bipolar disorder diagnosis, age 18-64 years, and a pharmacy benefit. Propensity scoring was used to control for differences between patients with and without 2 depression diagnoses in the year following their bipolar disorder diagnosis. Medical charts were obtained for 100 patients, including 76 with a bipolar disorder diagnosis chart from one provider and a depression diagnosis chart from a second provider.
Of 3119 bipolar disorder patients meeting inclusion criteria, 857 (27.5%) had subsequent depression misdiagnoses during the follow-up year. These patients had 1.82 times more psychiatric hospitalizations and 2.47 times more psychiatric emergency room visits. For 673 patients (78.5%), a different provider gave the depression misdiagnosis. Annual per-patient treatment costs were significantly higher (p < .001) for those diagnosed with depression ($12,594) than for those not ($9405). In the chart review, both the bipolar disorder and subsequent depression diagnoses were confirmed for 65.8% (50/76) of the patients who had charts from 2 different providers.
More than one quarter of individuals diagnosed with bipolar disorder received an ostensible depression misdiagnosis during the follow-up period. Significant (p = .001) increases in psychiatric inpatient hospitalization suggest that improvements in the continuity of care could improve outcomes and reduce costs.
双相情感障碍在医疗实践中诊断颇具挑战性。
我们的目标是:(1)确定行政索赔中先前被诊断为双相情感障碍的患者中抑郁症误诊率;(2)确定由此导致的治疗成本增加;(3)核实部分患者病历中的误诊情况。
我们采用队列分析,使用来自美国一家大型商业健康计划在2001年1月至2003年12月期间的索赔数据。纳入标准包括两次双相情感障碍诊断(ICD - 9 - CM标准)、在首次双相情感障碍诊断前后连续参保1年、年龄18 - 64岁以及享有药房福利。倾向评分用于控制双相情感障碍诊断后一年内有两次抑郁症诊断和无两次抑郁症诊断患者之间的差异。获取了100名患者的病历,其中76名患者有一位医生提供的双相情感障碍诊断病历以及另一位医生提供的抑郁症诊断病历。
在3119名符合纳入标准的双相情感障碍患者中,857名(27.5%)在随访年度出现后续抑郁症误诊。这些患者的精神科住院次数多1.82倍,精神科急诊就诊次数多2.47倍。对于673名患者(78.5%),抑郁症误诊是由不同医生做出的。被诊断为抑郁症的患者每人每年治疗成本显著更高(p <.001)(12,594美元),高于未被误诊的患者(9405美元)。在病历审查中,对于有两份来自不同医生病历的患者,65.8%(50/76)的患者双相情感障碍和后续抑郁症诊断均得到证实。
超过四分之一被诊断为双相情感障碍的个体在随访期间表面上被误诊为抑郁症。精神科住院显著增加(p =.001)表明改善护理连续性可改善治疗结果并降低成本。